Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-27T14:27:59.999Z Has data issue: false hasContentIssue false
  • English
  • Français

Results of Primary Treatment with Bromocriptine of Prolactinomas with Extrasellar Extension

Published online by Cambridge University Press:  18 September 2015

Johanna W. van't Verlaat ,
Ronald J.M. Croughs ,
Martin J. Hendriks  and
Nicolaas J. Bosma
Johanna W. van't Verlaat*
Affiliation:
Department of Neurosurgery, University Hospital Utrech, The Netherlands
Ronald J.M. Croughs
Affiliation:
Department of Endocrinology, University Hospital Utrech, The Netherlands
Martin J. Hendriks
Affiliation:
Department of Radiology, University Hospital Utrech, The Netherlands
Nicolaas J. Bosma
Affiliation:
Department of Neurosurgery, University Hospital Utrech, The Netherlands
*
Department of Neurosurgery, University Hospital Utrech, Aristoteleslaan I, 3707 E J Zeist, The Netherlands
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Nineteen patients, seven women and twelve men, with macroprolactinomas characterized by extrasellar extension and basal prolactin levels above 6 U/I were treated with 10-20 mg bromocriptine daily in four divided doses for a mean period of 3.4 years (range 1.5-5.5 years). Plasma prolactin levels fell dramatically in all patients and values in the low normal range were obtained in sixteen patients. Tumor size was reduced by more than 75% in seventeen patients and by 50-75% in two patients. Tumor reduction was associated with the development of a partial empty sella in fourteen cases. In seventeen cases the pituitary became visible. Diminished visual acuity (six patients), bitemporal hemianopia (nine patients), unilateral and bilateral central scotomas (three patients) and oculomotor palsy (two patients) improved or normalized in all cases. Hypogonadism (all patients), hypothyroidism (nine patients) and hypocorticism (four patients) improved or normalized in most cases. It is concluded that in the medical treatment of macroprolactinomas 10-20 mg bromocriptine in four divided doses effectively reduces both plasma prolactin level and tumor size. The good results in this study may be related to the continued use of a fixed dose regimen of bromocriptine regardless of the plasma prolactin lowering effect.

Type
Special Supplement - Secreting Pituitary Adenomas
Information
Canadian Journal of Neurological Sciences , Volume 17 , Issue 1 , February 1990 , pp. 71 - 73
Copyright
Copyright © Canadian Neurological Sciences Federation 1990

References

REFERENCES

1.Hardy, J, Beauregard, H, Robert, F.Prolactin secreting pituitary adenomas, transsphenoidal microsurgical treatment. Clin Neurosurg 1980; 27: 38–47.CrossRefGoogle ScholarPubMed
2.Grossman, A, Besser, GM.Prolactinomas. Br Med J 1985; 290: 182–184.CrossRefGoogle ScholarPubMed
3.Randall, RV, Laws, ER, Abboud, CF, et al. Transsphenoidal microsurgical treatment of prolactin-producing pituitary adenomas, results in 100 patients. Mayo Clin Proc 1983; 58: 108–121.Google ScholarPubMed
4.Vance, ML, Evans, WS, Thorner, MO.Diagnosis and treatment, drugs five years later, bromocriptine. Ann Intern Med 1984; 100: 78–91.CrossRefGoogle Scholar
5.Molitch, ME, Elton, RL, Blackwell, RE, et al. The bromocriptine study group, bromocriptine as primary therapy for prolactinsecreting macroadenomas, results of a prospective multicenter study. J Clin Endocrinol Metab 1985; 60: 698–705.CrossRefGoogle Scholar
6.Scotti, G, Scialfa, G, Pieralli, S, et al. Macroprolactinomas. CT evaluation of reduction of tumor size after medical treatment. Neuroradiology 1982; 23: 123–126.CrossRefGoogle ScholarPubMed
7.Wass, JAH, Williams, J, Charlesworth, M, et al. Bromocriptine in management of large pituitary tumors. Br Med J 1982; 284: 1908–1911.CrossRefGoogle Scholar
8.Liuzzi, A, Dallabonzana, D, Oppizzi, G, et al. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med 1985; 313: 656–659.CrossRefGoogle ScholarPubMed
9.Aubörg, PR, Derome, PJ, Peillon, F, et al. Endocrine outcome after transsphenoidal adenomectomy for prolactinoma, prolactin levels and tumor size as predicting factors. Surg Neurol 1980; 14: 141–143.Google Scholar
10.Rawe, SE, Williamson, HO, Levine, JH, et al. Prolactinomas, surgical therapy, indications and results. Surg Neurol 1980; 14: 161–167.Google ScholarPubMed
11.Faria, MA, Tindall, GT.Transsphenoidal microsurgery for prolactinsecreting pituitary adenomas. J Neurosurg 1982; 56: 33–43.CrossRefGoogle ScholarPubMed